Breckenridge Announces Tetracycline Capsules Launch
BOCA RATON, Fla., Feb. 12, 2019 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announced today the immediate launch of Tetracycline Capsules. The product is available in 250mg and 500mg strengths. Tetracycline Hydrochloride Capsules generated annual sales of $22 million dollars over the twelve months ending December 31, 2018, according to industry sales data. The U.S. Food and Drug Administration had granted final approval for this Abbreviated New Drug Application on November 7, 2018.
Breckenridge Pharmaceutical, Inc. is a privately-held own-label distributor that performs pharmaceutical marketing, research and development, as well as marketing and distribution in the U.S. The company was founded in 1983 and markets a broad range of generic prescription products in many therapeutic categories. The Breckenridge label is recognized by wholesalers, distributors, chains, and managed care accounts, as well as retail pharmacies nationwide. The company markets over 70 products in a variety of dosage forms including: tablets, capsules, liquids, suspensions, ophthalmics, nasal sprays, powders and injectable products.
MEDIKL, is a privately held pharmaceutical company founded in 2009. MEDIKL is committed to the development of a premium range of generic pharmaceutical products in a variety of dosage forms including: tablets, capsules, liquids and injectable products. The company has a multi-product agreement with Breckenridge for marketing its product's in the US market, with 5 additional products expected to be launched in the following 2 years.
SOURCE Breckenridge Pharmaceutical, Inc.